This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Inflammatory condition of skin
  • /
  • S3-Guideline on the Systemic Treatment of Psoriasi...

S3-Guideline on the Systemic Treatment of Psoriasis vulgaris (update- Apremilast, Secukinumab)

Read time: 1 mins
Last updated:14th Jun 2018
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations

An update of the European S3-Guidelines on the systemic treatment of psoriasis vulgaris – the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the International Psoriasis Council (IPC – was published in December 2015.1,2
In addition to the interventions discussed in the update, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved apremilast and secukinumab as new treatment options for psoriasis.
The European Commission granted a marketing authorization for both treatments on 15 January 2015.3,4 In February 2016, EMA also approved ixekizumab,5 which will be discussed in a further update as the expert group felt that at the time of the consensus conference, expert experience with ixekizumab was still too limited to allow conclusive discussion.


Read full guideline